scholarly journals A High Serum Phosphate and Calcium-Phosphate Product is Associated With Cerebral Small Vascular Disease in Patients With Stroke; A Real World Study

2021 ◽  
Author(s):  
Wenjing Lv ◽  
Zixuan Wang ◽  
junqi jiang ◽  
BinBin Deng ◽  
Qingxia Lin
Keyword(s):  
Calcium Phosphate ◽  
Vascular Disease ◽  
Real World ◽  
High Serum ◽  
Serum Phosphate ◽  
Phosphate Product

scholarly journals Bone metabolic disorder and its contributing factors in patients with chronic kidney disease; a three-year cohort study

2021 ◽  
Vol 11 (1) ◽  
pp. e5-e5
Author(s):  
Kourosh Eftekharian ◽  
Hassan Eftekhar Ardebili ◽  
Mohammad Hossein Shojamoradi ◽  
Sahar Samimi
Keyword(s):  
Chronic Kidney Disease ◽  
Cohort Study ◽  
Calcium Phosphate ◽  
Kidney Disease ◽  
Metabolic Disorder ◽  
Serum Phosphate ◽  
Phosphate Level ◽  
Advanced Stages ◽  
Phosphate Product ◽  
Bone Metabolic Disorder

Introduction: The prevalence of bone mineral disorder is best known in end-stage renal disease (ESRD) patients, but less data is available for the earlier stages. Objectives: We aimed to compare the prevalence of bone metabolic disorder at all stages of chronic kidney disease (CKD) and assess its contribution to CKD progression and patients’ outcome. Patients and Methods: In a retrospective cohort study, CKD patients who were under treatment for three years were selected from a nephrology clinic in Tehran, Iran. Patients’ demographic and laboratory data, as well as the outcome of their treatment were gathered and analyzed. Results: In 473 patients with an average age of 61.5, 60.1% were at stage III, 35.8% were at stage IV, and 4.1% were at stage V of CKD. There was a significant relationship between CKD stage and serum phosphate, calcium-phosphate product, and systolic blood pressure (SBP). Furthermore, the patients’ outcome was significantly related to advanced stages of CKD, higher first phosphate level, diabetes mellitus in medical history, and higher stages of SBP. By multiple Cox regression analysis, after adjustment for glomerular filtration rate (GFR), the first serum phosphate level, and the calcium-phosphate product did not contribute to the undesirable outcome. Conclusion: Although bone metabolic disorder is more frequently seen in advanced stages of chronic kidney disease, these changes can be seen even in earlier stages of the disease. The influence of phosphate abnormality in the patients’ outcome should be studied more in earlier stages for better control.

scholarly journals Association of Serum Calcium and Phosphate Concentrations with Glucose Metabolism Markers: The Furukawa Nutrition and Health Study

Nutrients ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2344
Author(s):  
Shamima Akter ◽  
Masafumi Eguchi ◽  
Takeshi Kochi ◽  
Isamu Kabe ◽  
Akiko Nanri ◽  
...  
Keyword(s):  
Calcium Phosphate ◽  
Glucose Metabolism ◽  
Serum Calcium ◽  
Serum Phosphate ◽  
Health Study ◽  
Model Assessment ◽  
Adjusted Means ◽  
Homeostatic Model Assessment ◽  
Phosphate Product ◽  
Homeostatic Model

Calcium and phosphate may play an important role in cardio-metabolic abnormalities, including type 2 diabetes; however, epidemiological evidence of the association of calcium and phosphate status with glucose metabolism among Asians is limited. In the current study, we performed a cross-sectional analysis of the association of serum calcium, phosphate, and calcium–phosphate product concentrations with glucose metabolism markers among Japanese individuals. Overall, 1701 workers (aged 18–78 years) who participated in a health survey were enrolled in this study. Multivariable linear regression models were used to estimate means of homeostatic model assessment of insulin resistance (HOMA-IR), homeostatic model assessment of β-cell function (HOMA-β), and glycated hemoglobin (HbA1c). Serum calcium concentration was positively associated with HOMA-IR and HbA1c (p for trend < 0.01). Multivariable-adjusted means (95% confidence interval (CI)) of HOMA-IR for the lowest and highest quartiles of serum calcium were 0.78 (0.75–0.82) and 1.01 (0.96–1.07), respectively. The corresponding values for HbA1c were 5.24 (5.22–5.27) and 5.29 (5.26–5.32), respectively. Serum phosphate and calcium–phosphate product concentrations were inversely associated with HOMA-IR (p for trend < 0.01). Multivariable-adjusted means (95% CI) of HOMA-IR for the lowest and highest quartiles of serum phosphate were 1.04 (0.99–1.09) and 0.72 (0.69–0.76), respectively. The corresponding values for calcium–phosphate product were 1.04 (0.99–1.09) and 0.73 (0.69–0.77), respectively. The current findings suggest that higher serum calcium and lower serum phosphate concentrations are associated with IR among apparently healthy adults.

scholarly journals Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial

2015 ◽  
Vol 113 (10) ◽  
pp. 1585-1594 ◽  
Author(s):  
Sarah M. Bristow ◽  
Gregory D. Gamble ◽  
Angela Stewart ◽  
Rama Kalluru ◽  
Anne M. Horne ◽  
...  
Keyword(s):  
Single Dose ◽  
Cardiovascular Risk ◽  
Calcium Phosphate ◽  
Serum Calcium ◽  
Dairy Product ◽  
Serum Phosphate ◽  
Calcium Citrate ◽  
Acute Effects ◽  
Phosphate Product ◽  
Different Sources

Ca supplements, but not dietary Ca, have been associated with increased cardiovascular risk. This difference could be related to differences in their acute effects on serum Ca. We therefore examined the effects of Ca from different sources on serum Ca and phosphate in a randomised, cross-over trial of ten women (mean age of 69 years). Fasting participants received a single dose of 500 mg of Ca as citrate, citrate with a meal, fortified juice or a dairy product meal, with at least 6 d between each intervention. Blood was sampled before and 1, 2, 4 and 6 h after each intervention was ingested. Serum ionised and total Ca increased significantly from baseline over 6 h. Using calcium citrate fasting as a comparator, the elevations in ionised and total Ca were similar after fortified juice, delayed after calcium citrate with a meal and smaller after a dairy product meal. Serum phosphate and calcium–phosphate product increased from baseline after calcium citrate with a meal and after a dairy product meal, and they declined after calcium citrate fasting and after fortified juice. The elevations in serum Ca in the present study were only slightly different from those observed after the administration of 1000 mg of Ca in a previous study. These data indicate that different sources of Ca have different acute effects on serum Ca and support recommendations that dietary Ca might be safer than supplements. Whether these differences contribute to differences in cardiovascular risk requires further study.

Abstract P285: Pattern of Atrial Fibrillation and Risk of Outcomes: The Loire Valley Atrial Fibrillation Project

Circulation ◽  
2012 ◽  
Vol 125 (suppl_10) ◽  
Author(s):  
Amitava Banerjee ◽  
Sophie Taillandier ◽  
Jonas B Olesen ◽  
Deirdre A Lane ◽  
Benedicte Lallemand ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Vascular Disease ◽  
Real World ◽  
Cox Regression ◽  
Multivariate Analyses ◽  
Prior History ◽  
Previous Stroke ◽  
Hospital Institution

Background: The risk of stroke and thromboembolism (TE) in patients with non-valvular atrial fibrillation (NVAF) can be classified in commonly-used stroke risk stratification scores. The role of the pattern of atrial fibrillation in risk prediction is unclear in contemporary ‘real world’ cohorts. Methods: Patients diagnosed with NVAF in a four-hospital-institution between 2000 and 2010 were identified and included. Event rates of stroke/TE were calculated according to pattern of AF, i.e. paroxysmal, persistent and permanent, defined by consensus guidelines. Independent risk factors of stroke/TE were investigated by Cox regression. Results: Among 7156 patients with NVAF, 4176 (58.4%) patients with paroxysmal, 376 (5.3%) with persistent and 2604 (36.3%) with permanent NVAF patterns were included. In non-anticoagulated patients, the overall stroke/TE event rate per 100 person-years was 1.29 (95% CI 1.13–1.47). Paroxysmal NVAF patients were more likely to be female (p<0.001). Persistent NVAF patients were less likely to have prior history of stroke (p–0.002) and vascular disease (p<0.001), and more likely to have hypertension (p<0.001) and vitamin K antagonist therapy (p<0.001). Permanent NVAF patients were more likely to have diabetes (p<0.001), heart failure therapy (p<0.001) and less likely to have dyslipidaemia (p<0.001). Compared with paroxysmal NVAF, rates of stroke/TE (p=0.001), bleeding (p<0.001) and all-cause mortality (p<0.001) were significantly higher in permanent NVAF patients but not in persistent NVAF patients. In multivariate analyses, only previous stroke (hazard ratio, HR 2.58, 95% CI 2.08–3.21), vascular disease (HR 1.34,1.12–1.61), heart failure (HR 1.20,1.00–1.44), age≥75 years (HR 2.75, 2.16–3.50) and age 65–74 years (HR 1.60,1.22–2.09) increased stroke/TE risk, but persistent (HR1.13, 0.76–1.70) and permanent (HR 1.44,0.96–2.16) patterns of NVAF did not. Conclusion: In this large ‘real world’ cohort of NVAF patients, there were significant differences in rates of stroke, TE, death and bleeding between patterns of NVAF, however only previous stroke, age, heart failure and vascular disease (not pattern of NVAF) independently increased the risk of stroke/TE, death and bleeding in multivariate analyses. Therefore, the risk of stroke is similar across all patterns of NVAF and antithrombotic therapy should be based on clinical risk factors not NVAF pattern.

Calcium phosphate product level as a predictor for arteriovenous fistula re-operations in patients with chronic renal failure

Vascular ◽  
2018 ◽  
Vol 27 (3) ◽  
pp. 284-290 ◽  
Author(s):  
Mehmet Erin Tüysüz ◽  
Mehmet Dedemoğlu
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Calcium Phosphate ◽  
Arteriovenous Fistula ◽  
Product Level ◽  
Increased Risk ◽  
High Calcium ◽  
Phosphate Product ◽  
Group 2 ◽  
Group 1

Objectives There is an increased calcium phosphate product level causing the formation of calcification in the arterial wall and thus decreased quality of fistula in patients with chronic renal failure. The purpose of our study is to verify the relationship between arteriovenous fistula re-operation and high calcium phosphate product level. Methods Seventy-nine consecutive patients with chronic renal failure between April 2016 and February 2018 were included in the study. Patients having calcium phosphate product level ≥50 mg2/dl2 were defined as group 1, whereas those having <50 mg2/dl2 were defined as group 2. Primary outcome of interest was the need for re-operation during the follow-up and to determine the risk factors for re-operation. To determine independent predictors for re-operation, multivariate logistic regression model was used. Results The rates of redo and tredo operation were significantly higher in group 1 compared to group 2 ( p = 0.01 and 0.04). In multivariate analysis, phosphate (OR: 1.84, 95% CI: 1.00–3.40, p = 0.05) and triglyceride (OR: 1.01, 95% CI: 1.00–1.02, p = 0.04) levels for redo operation and calcium phosphate product level (OR: 1.11, 95% CI: 1.01–1.22, p = 0.03) for tredo operation were found to be independent predictors. Conclusions High calcium phosphate product level leads to increased risk of arteriovenous fistula re-operation by causing arterial stiffness in this patient group. Additionally, these re-operations place additional burden on morbidity and cost efficacy. Thus, we recommend keeping the calcium phosphate product level at the optimal level in these patients to avoid both the risk of arteriovenous fistula re-operation and the other cardiovascular problems.

PREVENTION OF CUTANEOUS CALCIPHYLAXIS IN CALCIUM-DEFICIENT RATS

1965 ◽  
Vol 43 (2) ◽  
pp. 235-240 ◽  
Author(s):  
Pierre Jean ◽  
Denis Desaulniers
Keyword(s):  
Calcium Phosphate ◽  
Serum Calcium ◽  
Dietary Calcium ◽  
Deficient Diet ◽  
Phosphate Product

Dietary calcium is essential for the production of skin calcification in rats calciphylactically sensitized with dihydrotachysterol (DHT) and challenged with FeCl3 injection, or with the mild trauma of epilation. A calcium-deficient diet delays the rise in serum calcium after the administration of DHT. A comparatively lower calcium–phosphate product at the time of challenge could explain the absence of skin calcification in these animals.

scholarly journals Influence of Serum Biochemistry on Bone and Kidney Phenotypes in Subjects With Symptomatic Primary Hyperparathyroidism

2021 ◽  
Author(s):  
Mainak Banerjee ◽  
Jan Ahamed ◽  
Subhankar Chowdhury ◽  
Satinath Mukhopadhyay
Keyword(s):  
Renal Function ◽  
Calcium Phosphate ◽  
Serum Calcium ◽  
Bone Disease ◽  
Impaired Renal Function ◽  
Serum Biochemistry ◽  
Clinical Fractures ◽  
25 Hydroxy Vitamin D ◽  
Phosphate Product ◽  
Patient Subgroups

Abstract OBJECTIVETo analyze the abnormalities in serum parathormone (PTH)-25-hydroxy-vitamin D (25-OHD) axis and calcium phosphate homeostasis in symptomatic PHPT patients having bone disease, nephrolithiasis and impaired renal function (IRF) at diagnosis. METHODSConsecutive adults (>18 years) with diagnosed symptomatic PHPT were enrolled in the retrospective study. Relevant clinical, biochemical and imaging parameters were recorded.RESULTSAdult patients with symptomatic PHPT were identified (N=60, age 45.2±14.4 years, 45 females). Predominant phenotypes were bone disease (osteoporosis and/or clinical fractures, n=42, 70%) and nephrolithiasis (n=24, 40%). Compared to patients with nephrolithiasis only (subgroup C, n=7) and simultaneous bone disease/nephrolithiasis (subgroup D, n=17), patients with isolated bone disease phenotype (subgroup B, n=25) had significantly higher alkaline phosphatase (AlP) and lower 25-OHD levels at presentation. Patient subgroups with nephrolithiasis had higher serum calcium levels and lower effective glomerular filtration rate (eGFR) at presentation. PTH was not significantly different among these subgroups. Patients with IRF (eGFR <60 ml/min per 1.73 m2, n=17) in our cohort had significantly higher serum calcium, phosphate, PTH levels and nephrolithiasis rates. Presence of nephrolithiasis, higher calcium x phosphate product (IRF: 36.2 ± 10.7 versus no IRF: 26.2 ± 5.7 mg2/dl2) and increased PTH levels were independently associated with IRF at diagnosis.CONCLUSIONSWhile PHPT patients with isolated bone disease were found to have lower 25-OHD and higher AlP levels independent of PTH levels; PTH was found to be an independent predictor of impaired renal function at diagnosis.

Sign in / Sign up

Export Citation Format

Share Document